Zacks

Zacks Small Cap Analysis – IMNN: Outcomes from OVATION 2 Examine in Mid-2024… Educated

by

By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Enterprise Replace Topline Knowledge from OVATION 2 Trial Anticipated in Mid-2024 Imunon, Inc. (NASDAQ:IMNN) is at present conducting the Section 1/2 OVATION 2 trial of IMNN-001, the corporate’s IL-12 gene-mediated immunotherapy that’s primarily based on the TheraPlas expertise. The OVATION 2 examine is evaluating … Read more

Zacks Small Cap Analysis – XFOR: XOLREMDI Permitted by FDA…

by

By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Enterprise Replace XOLREMDI Permitted by the FDA On April 29, 2024, X4 Prescription drugs, Inc. (NASDAQ:XFOR) introduced that the U.S. Meals and Drug Administration (FDA) has authorised XOLREMDI (mavorixafor) to be used in sufferers 12 years of age and older with WHIM syndrome (warts, … Read more